Skip to main content
RecallRadar
FDAClass II

Theophylline Extended-Release Tablets, 200 mg, Rx Only, 100-count bottle, Distributed by:… Recalled: CGMP Deviations: interruption in the ongoing stability testing program conducted at a thi…

Theophylline Extended-Release Tablets, 200 mg, Rx Only,… was recalled on October 6, 2026 in cooperation with the U.S. Food and Drug Administration because CGMP Deviations: interruption in the ongoing stability testing program conducted at a third-party laboratory.

Is my unit affected?

Theophylline Extended-Release Tablets, 200 mg, Rx Only, 100-count bottle, Distributed by: Brandywine Pharmaceuticals, LLC, West Chester, PA 19382, NDC: 71321-501-10.

Model, lot & date codes to check

Lot: 405620, Expiry: 03/31/2028.

Units affected: 1,332 100-count bottles

Where it was sold: Nationwide within U.S

Compare the codes above against the label on your product — usually on the bottom, the back panel, or the packaging. If your unit isn't listed, it is not part of this recall.

What's the hazard?

CGMP Deviations: interruption in the ongoing stability testing program conducted at a third-party laboratory

Class II means the product might cause a temporary or medically reversible health problem; the chance of serious harm is remote.

Your remedy & how to claim it

Stop using the product. Return it to the place of purchase for a refund, or dispose of it. Contact the recalling firm with questions.

Contact: Recalling firm: Brandywine Pharmaceuticals, LLC

Not sure what you're entitled to? Read our guide: what to do if your product is recalled.

Official recall notice

Always confirm details on the official notice from the U.S. Food and Drug Administration before acting.

View official notice →

Get recall alerts

Be the first to know when products like this are recalled. Free weekly digest, unsubscribe anytime.

Double opt-in: we only email you after you confirm. No spam, ever.